AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include marketscreener.com, Bloomberg.com, MarketWatch and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 139d ago.
Quick answers
Why is "AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- AbbVie to Reportedly Buy Apogee Therapeutics in $10.9 Billion Deal marketscreener.com · 143d ago
- AbbVie Approaching $11 Billion Deal for Apogee Therapeutics, Report Says Bloomberg.com · 143d ago
- AbbVie would gain an experimental eczema drug by buying biotech: report MarketWatch · 143d ago
- AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics Seeking Alpha · 143d ago
- AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics Financial Times · 143d ago
- AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports Reuters · 143d ago
Topics
Related trends
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Former Apogee executives join Paragon Labs to scale R&D following an acquisition, while Alaunos Therapeutics secures major financing.
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.